



Original Research

Evaluation of the effects of *Cyclotrichium niveum* on brain acetylcholinesterase activity and oxidative stress in male rats orally exposed to lead acetate

Zafer Sahin^{1*}, Ahmet Ozkaya², Mirac Uckun³, Ertan Yologlu⁴, Muslum Kuzu⁵, Veysel Comakli⁶, Ramazan Demirdag⁶, Ahmet Zafer Tel⁷, Fatih Aymelek⁸, Semra Yologlu²

¹Department of Physiology, Faculty of Medicine, Karadeniz Technical University, Trabzon, Turkey

²Department of Chemistry, Faculty of Science and Art, Adiyaman University, Adiyaman, Turkey

³Department of Food Engineering, Faculty of Engineering, Adiyaman University, Adiyaman, Turkey

⁴Department of Science Education, Faculty of Education, Adiyaman University, Adiyaman, Turkey

⁵Faculty of Pharmacy, Agri Ibrahim Cecen University, Agri, Turkey

⁶School of Health, Agri Ibrahim Cecen University, Agri, Turkey

⁷Department of Biology, Faculty of Science and Art, Adiyaman University, Adiyaman, Turkey

⁸Central Research Laboratory, Adiyaman University, Adiyaman, Turkey

*Correspondence to: zafersahin55@yahoo.com

Received January 1, 2018; Accepted May 15, 2019; Published June 30, 2019

Doi: <http://dx.doi.org/10.14715/cmb/2019.65.5.2>

Copyright: © 2019 by the C.M.B. Association. All rights reserved.

Abstract: *Cyclotrichium niveum* is an endemic plant for Turkey and it appears to have in vitro antioxidant and acetylcholinesterase inhibition properties. To the best of our knowledge, there has been no study on the in vivo effects of this plant. Therefore, the purpose of this study was to evaluate the effects of *C. niveum* on lead (Pb)-acetate-induced potential alterations in brain acetylcholinesterase activity, as well as oxidative stress in male rats. The rats were randomly assigned to control, Pb-acetate, *C. niveum* and Pb-acetate+ *C. niveum* groups. Pb-acetate was provided in drinking water (500 ppm), and *C. niveum* was administered via orogastric gavage (4 ml/kg) for 30 days. The acetylcholinesterase activity in the brain significantly decreased only in the Pb-acetate group. The malondialdehyde level significantly increased, and the reduced glutathione activity decreased in the Pb-acetate group. The reduced glutathione and glutathione-S-transferase activities of the *C. niveum* group were higher than the control group. No Pb was detected on a ppb level in the brain tissue of the control and *C. niveum* groups, while it was detected in the brains of the rats in the Pb-acetate and Pb-acetate+ *C. niveum* groups (185+8.98 ppb and 206+56.65 ppb, respectively). The data collected in this study suggested that *C. niveum* may reduce inhibition of brain AChE activity and oxidative stress against Pb-acetate-induced alterations in the brain of male rats.

Key words: *Cyclotrichium niveum*; Lead acetate; Brain; Acetylcholinesterase; Oxidative stress.

Introduction

Lead (Pb) is one of the most widely and versatilely used metals in the industry. Most individuals may be exposed to this metal by ingesting contaminated food and water, as well as contaminated materials and dust (1). Once penetrated into the body, Pb has a wide range of destructive effects on many organs, and it induces various physiological and behavioral alterations (2-4). The central nervous system is particularly susceptible to the negative effects of Pb, which has been reported to induce damage in the brain through several direct and indirect pathways such as apoptosis, neurotransmitter dysregulations and oxidative stress (4-6).

Medicinal plants are increasingly important targets as options for discovering new commercial drugs. It is estimated that approximately one-third of the most widely used ways of medication in the world involve natural products or their derivatives (6). In this context, one plant that has attracted interest is *Cyclotrichium niveum*, which is an endemic species for Turkey and a member of the family Lamiaceae. This plant grows in the Eastern Anatolia Region and its local name is 'dağ

nanesi' in Turkish (7). It has a distinct minty smell, and it is used in making soup and herbal teas, while it is also used as food flavoring in Turkey (8, 9). Previous studies on the pharmacological roles of *C. niveum* revealed that the aqueous and ethanol extracts of this plant possessed in vitro antioxidant, antimicrobial and antispasmodic effects (9-12). Moreover, a study suggested that *C. niveum* has an in vitro acetylcholinesterase (AChE) inhibitory effect (13).

Many researchers reported that Pb exposure may alter AChE activities (14-16). Moreover, oxidative damage is considered to be a crucial factor in Pb-induced neurotoxicity (16, 17). To the best of our knowledge, there is no study relating the in vivo AChE activity and the antioxidant potential of *C. niveum*. Therefore, the aim of this study was to evaluate the effects of an aqueous extract of *C. niveum* on the brain AChE activity, as well as malondialdehyde, reduced glutathione, glutathione reductase, glutathione S-transferase and Pb concentration against Pb-acetate-induced neurotoxicity in rats.

Materials and Methods

Animals and chemicals

Twenty-eight adult Wistar albino male rats (320-340 g body weight) were obtained from the Experimental Research Unit of Firat University (Elazig, Turkey). The animals were housed under a standard light/darkness cycle (lights on from 07:00 to 19:00 h), at a regular temperature (21 ± 1 °C) and humidity ($55 \pm 5\%$) with free access to food and fresh water. The experimental protocols were approved by the Ethical Committee of Firat University, and the rats were treated in accordance with the national and international laws and policies on the care and use of laboratory animals.

Pb-acetate, acetic acid and other chemicals were obtained from Sigma (Dorset, UK) unless otherwise stated.

Plant Material and Extraction Procedures

C. niveum plants (Herbarium no: 1383) were collected by Dr. Ahmet Zafer TEL from Nemrut Mountain (Adiyaman, coordinates: 38°1.065' N - 38°43.461' E and altitude: 1383 m) with the permission of the Governorship of Adiyaman, the Provincial Directorate of Food, Agriculture and Livestock (permission number: 44109306/7467-1190).

Extraction was carried out as previously described by Gulcin *et al.* (9). Briefly, the plants were dried in the shade first. For water extraction, 25 g of air-dried aerial parts of *C. niveum* was ground into a fine powder in a mill and mixed with 400 ml of boiling water by a magnetic stirrer for 15 min. The extract was then filtered through a colander.

Experimental design

The animals were randomly divided into four groups as control, Pb-acetate, *C. niveum* and Pb-acetate+*C. niveum* ($n=7$ in each group). The control group rats received vehicle solutions only. *C. niveum* was administered orally (4 ml/kg) to the animals via orogastric gavage for 30 days. In the Pb-acetate and Pb-acetate+ *C. niveum* groups, the rats were given a daily dose of 500 ppm of Pb-acetate (dissolved in acetic acid) per liter in drinking water for 30 days (3). The animals were sacrificed at the end of 30 days. The brains were removed from the animals. For biochemical analyses, the brain samples were stored at -20 °C until the assays were performed.

Tissue homogenization

The homogenization of the brain samples was performed using a polytron homogenizer (Heidolph RZ 2021, Germany) in a cooled homogenization buffer (0.1 M, pH 7.4 in potassium phosphate buffer; 0.15M KCl, 1mM EDTA, 1mM DTT) at 4 times the total tissue weight (w/v). After homogenization, the homogenates were transferred into Eppendorf tubes and centrifuged at 16,000g for 20 min at 4 °C (Sigma Centrifuge Model 2-16K, Sigma, St. Louis, MO). After centrifugation, the supernatant fraction was removed and enzyme activities and other parameters were measured in S16 fractions. Three replicate absorbance readings were made for each sample, and the reading was repeated when there was a correlation difference greater than 10% between the

values obtained for the same samples.

Analyses of brain AChE activity

Brain AChE activity was analyzed according to the method described by Ellman and Andres (18) with some modifications (19) for a microplate reader spectrophotometer system (Thermo™ Varioskan Flash, Thermo Scientific, Vantaa, Finland). In the activity assay, acetylcholine iodide (ACTI) was used as the substrate and product formation was determined by color change. For this purpose, the supernatant (10 µl volume) was pipetted into the microplate wells. Thereafter, the final solution was prepared in 0.1 M of buffer (pH 8.0) as 200 µl (0.701 mM ACTI and 0.136 mM 5.5-dithiobis-2-nitro-benzoic acid (DTNB) and transferred into the microplate wells. The change in absorbance was recorded at 412 nm for 1 minute at 25 °C. Specific AChE activity was calculated as nmol/min/mg protein.

The total protein amounts in the tissue homogenates were determined based on the method developed by Bradford (20). After dilution (1:4), 5 µl of the diluted sample and 250 µl of the Bradford solution were added into the microplate wells in this order. The reaction mixture was incubated at room temperature for at least 15 minutes in the dark. Depending on the color change, the absorbance value was measured at a wavelength of 595 nm.

Determination of brain malondialdehyde (MDA) and reduced GSH levels

MDA, reduced GSH, GR and GST levels were determined using a microplate reader spectrophotometer system (Thermo™ Varioskan Flash, Thermo Scientific, Vantaa, Finland). The brain malondialdehyde levels were measured based on the relative production of the reactive substances of thiobarbituric acid (21). The results are represented as nmol/g wet tissue weight. The reduced GSH activity was measured by the substance's reaction with DTNB, to form a compound that absorbs at 412 nm (22). The level of reduced GSH is expressed as nmol/g wet weight tissue.

Measurement of brain glutathione reductase (GR) and glutathione S-transferase (GST) activities

Analysis of GR activity was determined by a modified method (23). The assay solution contained 50 mM of Tris-HCl buffer (pH 8.0), 1 mM of EDTA, 1 mM of GSSG and 0.1 mM of NADPH. One enzyme unit was defined as the amount that oxidizes 1 µmol NADPH per min under the assay conditions. For determining GST activity, firstly 20 mM of 1-chloro-2,4- dinitrobenzene (CDNB) was prepared in 96% ethanol, and this solution was used as the substrate. Reductive glutathione (0.002 M) was used as the cofactor in the reaction (24). 10 µL of the supernatant, 100 µL of the phosphate buffer (0.1 M, pH 6.5) + 100 µL of the GSH mixture and finally 10 µL of CDNB were transferred into the wells of the microplate. After this process, the well plates were placed in the microplate reader system, and the change in absorbance was recorded at 344 nm for 2 min at 25 °C. Specific GST activity was calculated as nmol/min/mg protein.

Determination of brain Pb concentrations

The brain Pb levels were measured using a NexION 350 inductively coupled plasma mass spectrometer (ICP-MS, Perkin Elmer, MA, USA) at the Central Research Laboratory of Adiyaman University. The tissue samples were digested in an acid solution using a microwave digestion system. For this purpose, the brain samples (250 mg) were placed into a digestion vessel, 5 ml of nitric acid (65%) was added, and the mixture was carefully shaken. The samples were then heated in a microwave oven in accordance with the digestion procedure described by Rattanachongkiat *et al.* (25).

The digestion solutions were diluted and analyzed using a NexION 350 series of the ICP-MS. For quality control, duplicate samples were used to measure the precision of the analysis. Detection limits were calculated as three times the standard deviation for the reagent blanks (26). The results of the brain Pb concentrations are presented as ppb.

Statistical analysis

All results are expressed as mean ± SEM. The comparison of the groups was carried out using one-way analysis of variance (ANOVA) followed by Tukey–HSD test. Statistical significance was accepted as $P < 0.05$.

Results

Brain AChE activity

Fig. 1 shows the findings on the brain AChE activity. The AChE activity significantly decreased in comparison to the control group only in the Pb-acetate group (21.07 ± 3.84 nmol/min/mg protein and 13.70 ± 2.48 nmol/min/mg protein, respectively, $P < 0.05$). The AChE activities of the *C. niveum* (22.15 ± 3.60 nmol/min/mg protein) and Pb-acetate+*C. niveum* (17.42 ± 1.36 nmol/min/mg protein) groups did not differ significantly from the control group. When compared with the Pb-acetate group, the brain AChE activity was higher in the *C. niveum* group ($P < 0.05$).

Findings on the brain MDA and reduced GSH analysis

The brain MDA concentration of the Pb-acetate group was significantly higher than the control group (470 ± 20 nmol/gr and 415 ± 12 nmol/gr, respectively, $P < 0.05$). There was no significant difference in the *C. niveum* group (386 ± 20 nmol/gr) and Pb-acetate+*C. niveum*

group (394 ± 36 nmol/gr) in comparison to the control group. When compared with the Pb-acetate group, the brain MDA levels were lower in the *C. niveum* group and the Pb-acetate+*C. niveum* group ($P < 0.01$ and $P < 0.05$, respectively, Fig. 2). The brain reduced GSH level was significantly lower in the Pb-acetate group than the control group (0.635 ± 0.2 nmol/gr and 1.21 ± 0.2 nmol/gr, respectively, $P < 0.05$). Although the difference was not significant, the brain reduced GSH concentrations were higher in the *C. niveum* group (1.95 ± 0.5 nmol/gr) and Pb-acetate+*C. niveum* group (1.74 ± 0.7 nmol/gr) in comparison to the control group. In the *C. niveum* group and the Pb-acetate+*C. niveum* group, the brain reduced GSH levels were higher than the Pb-acetate group ($P < 0.01$ and $P < 0.05$, respectively, Figure 3).

Activities of the brain GR and GST

The mean GR activity (EU/mg protein, Fig. 4)




Figure 2. Effects of Pb-acetate and *C. niveum* on the MDA level in male rat brain. The data represent mean ± SEM (n=7). *: $p < 0.05$ compared to the control group. #: $p < 0.05$ and ##: $p < 0.01$ compared to the Pb-acetate group. MDA: Malondialdehyde, Pb: lead.




Figure 3. Effects of Pb-acetate and *C. niveum* on the reduced GSH level in male rat brain. The data represent mean ± SEM (n=7). *: $p < 0.05$ compared to the control group. #: $p < 0.05$ and ##: $p < 0.01$ compared to the Pb-acetate group. GSH: Glutathione, Pb: lead.




Figure 1. Effects of Pb-acetate and *C. niveum* on the AChE activity in male rat brain. The data represent mean ± SEM (n=7). *: $p < 0.05$ compared to the control group. #: $p < 0.05$ compared to the Pb-acetate group. AChE: Acetylcholinesterase, Pb: lead.




Figure 4. Effects of Pb-acetate and *C. niveum* on the GR activity in male rat brain. The data represent mean ± SEM (n=7). GR: Glutathione reductase, Pb: lead.

significantly declined only in the Pb-acetate group (0.00558 ± 0.0007 , $P < 0.05$). There was no significant difference in the *C. niveum* group (0.00655 ± 0.0007) and Pb-acetate+*C. niveum* group (0.00601 ± 0.0008) in comparison to the control group (0.0068 ± 0.0005).

Fig. 5 shows the findings on brain GST activity (nmol/min/mg protein). Although the difference was not significant, the brain GST activity was higher in the *C. niveum* group (35.05 ± 5.40) and lower in the Pb-acetate group (24.43 ± 3.03) in comparison to the control group (29.36 ± 3.47). The value of the GST activity in the Pb-acetate+*C. niveum* group (30.31 ± 4.87) was on the same level as the control group. When compared with the Pb-acetate group, the brain GST activity was significantly higher in the *C. niveum* group ($P < 0.05$).

Findings on the brain Pb analysis

Pb was not detected on the level of ppb in the brain samples of the control and the *C. niveum* groups. Pb was detected in the brain samples of the Pb-acetate group (185 ± 8.98) and the Pb-acetate+*C. niveum* group (206 ± 56.65). However, the Pb concentrations did not significantly differ between the Pb-acetate group and Pb-acetate+*C. niveum* group (Fig. 6).

Discussion

This study is the first to evaluate the *in vivo* AChE activity and antioxidant potential of an aqueous extract of *C. niveum* in rats exposed to Pb-acetate. In the experiment presented here, we observed that the brain AChE activity significantly decreased only in the Pb-acetate group. There are many *in vitro* (16) and *in vivo* (14, 15, 27, 28) studies on the AChE inhibition effects of Pb-acetate. Our results are consistent with these reports. Basha *et al.* (15) reported that Pb can mimic Ca^{2+} to AChE. Therefore, this interaction may inhibit the accessibility of Ca^{2+} , thus leading to decreased enzyme activity. There is only one *in vitro* study where dichloromethane and ethyl acetate extracts of *C. niveum* possessed an AChE inhibitory effect, but its essential oil as well as ethanol and aqueous extracts did not exhibit an anti-AChE effect (13). In our experiment, we used an aqueous extract of this plant and observed that AChE activity of the *C. niveum* group did not significantly differ from the control group. Interestingly, the AChE activity decreased in the Pb-acetate group, but the activity in the Pb-acetate+*C. niveum* group did not differ from the control group. Therefore, this result indicates that *C. niveum* may prevent inhibition of brain AChE activity caused by Pb-acetate. We only used an aqueous extract and a single dose of *C. niveum*. For this reason, determination of the effects of distinct extracts (dichloromethane, ethanol, ethyl acetate) and different doses of this plant is important for assessing potential pharmacological options. There have been a few studies on the essential oil of *C. niveum* of Turkish origin. Baser *et al.* (7) noted that the major constituents of this plant are pulegone (32.5–56.4%) and isomenthone (34.2–35.4%). Additionally, Cetinus *et al.* (10 2007) reported that pulegone (76.84%) is the main component in *C. niveum*'s essential oil. In our previous study, we observed that these components of *C. niveum* may negatively or positively alter due to altitude differences. The major




Figure 5. Effects of Pb-acetate and *C. niveum* on the GST activity in male rat brain. The data represent mean ± SEM (n=7). #: $p < 0.05$ compared to the Pb-acetate group GST: Glutathione S-transferase, Pb: lead.




Figure 6. Brain Pb concentrations. The data represent mean ± SEM (n=7). Pb: lead.

constituents of our plant samples were defined (29) as pulegone (65.23%), exo-isocamphonone (10.02%), isomenthone (7.23%), and limonene (2.57%).

Regarding the antioxidant activity of *C. niveum*, we observed that the brain MDA level increased only in the Pb-acetate-treated group. The reduced GSH level and GR activity significantly decreased in the Pb-acetate group. Although the difference was not significant, the GST activities of the *C. niveum* and Pb-acetate+*C. niveum* groups were higher than the control group. It is known that chronic exposure to lead acetate leads to an increase in lipid peroxidation and a decrease in reduced GSH (5, 30), GR, and GST activities in the brains of rats (5). Changes in the reduced GSH level, GR and partly GST activities may cause disturbances in the GSH antioxidant system in the brain. Therefore, we suggest that *C. niveum* has an improved effect on these antioxidant parameters against Pb-acetate-induced alterations. Pb can exclusively bind to the sulfhydryl group and cause a decrease in the GSH antioxidant system in the body (31). In physiological conditions, oxidized glutathione disulfide is reduced to GSH by GR at the expense of reduced nicotinamide adenine dinucleotide phosphate (NADPH) levels, thereby forming a redox cycle (32). The GR redox cycle is responsible for the maintenance of proper GSH concentration in the body (33). GSH is also involved in detoxication of many xenobiotics through the formation of S-conjugates with toxic metabolites in the second phase of biotransformation (34, 35). GSH also forms S-conjugates with products of lipid peroxidation (36, 37). The reaction of S-conjugation may be accelerated by GST (35). With our findings, these reports revealed that lead inactivates GR, GST and other related enzymes, which further depresses the

glutathione antioxidant system in the brain. This effect may also occur in other organs such as the liver (3, 38). In 2015, we reported that lead acetate causes a decrease in glucose 6-phosphate dehydrogenase (G6PD) and 6-phosphogluconate dehydrogenase (6PGD) enzyme activities in the erythrocytes of rats. These enzymes are involved in the oxidative reactions of the pentose phosphate pathway. In particular, the G6PD enzyme is responsible for the production of NADPH, which is very important for the detoxification and synthesis reactions in cells (2). All of these results indicate that lead exposure may cause a multifaceted pathophysiological disorder in the brain and other areas of the body.

We also evaluated the brain Pb levels and determined that the Pb concentration of the Pb-acetate-treated group did not significantly differ from the Pb-acetate+C. *niveum* group (185±8.98 ppb and 206±56.65 ppb, respectively). However, we did not find Pb on the ppb level in the control and *C. niveum* groups. Our results indicate that *C. niveum* has an antioxidant potential, but it has no chelating activity on Pb-acetate in the brain.

In conclusion, this study which firstly examined the *in vivo* neuroprotective role of an aqueous extract of *C. niveum* for the first time in a rat model of oral Pb exposure suggests that *C. niveum* has an ameliorative potential on Pb-acetate-induced inhibition of AChE activity, and this endemic plant exerts an antioxidant effect against Pb-acetate-caused oxidative stress in the brains of male rats. Further studies are needed to confirm *C. niveum*'s mechanism of action and better understand the way it modulates the brain functions.

Acknowledgments

This study was supported by Adiyaman University Scientific Research Projects Unit (ADYUBAP, Project no. FEFMAP/2015–0008).

Interest conflict

The authors declare no conflict of interest.

Author's contribution

Each author has made an important scientific contribution to the study and has assisted with the drafting of the manuscript.

References

1. Gracia RC, Snodgrass WR. Lead toxicity and chelation therapy. *Am J Health Syst Pharm* 2007; 64:45-53.
2. Demirdag R, Comakli V, Ozkaya A, Sahin Z, Dag U, Yerlikaya E, et al. Examination of changes in enzyme activities of erythrocyte glucose 6-phosphate dehydrogenase and 6-phosphogluconate dehydrogenase in rats given Naringenin and Lead acetate. *J Biochem Mol Toxicol* 2015; 29(1):43-7.
3. Ozkaya A, Sahin Z, Dag U, Ozkaraca M. Effects of Naringenin on Oxidative Stress and Histopathological Changes in the Liver of Lead Acetate Administered Rats. *J Biochem Mol Toxicol* 2016; 30(5):243-8.
4. Abdel Moneim AE. Flaxseed oil as a neuroprotective agent on lead acetate-induced monoaminergic alterations and neurotoxicity in rats. *Biol Trace Elem Res* 2012; 148:363–370.
5. Abdel Moneim AE, Dkhil MA, Al-Quraishy S. Effects of flaxseed oil on lead acetate-induced neurotoxicity in rats. *Biol Trace Elem Res* 2011; 144(1-3):904-13.

6. Strohl WR. 2000. The role of natural products in a modern drug discovery program. *Drug Discov Today* 2000; 5(2):39-41.
7. Baser KHC, Sarikardasoglu S, Tümen G. The Essential Oil of *Cyclotrichium niveum* (Boiss.) Manden. *Et Scheng. J Essen Oil Res* 1994; 6:9-12.
8. Baytop T. *Turkce bitki adlari sozlugu* (A dictionary of vernacular names of wild plants of Turkey). Publication of the Turk Dil Kurumu (The Turkish Language Society), Ankara, 1997 vol. 578.
9. Gülcin I, Tel AZ, Kirecci E. Antioxidant, antimicrobial, antifungal, and antiradical activities of *Cyclotrichium niveum* (Boiss.) Manden & Scheng. *Int J Food Crops* 2008; 11:450–471.
10. Cetinus SA, Goze I, Sarac B, Vural N. Scavenging effect and antispasmodic activity of the essential oil of *Cyclotrichium niveum*. *Fitoterapia* 2007; 78(2):129-133.
11. Emen S, Ceken B, Kizil G, Kizil M. DNA damage protecting activity and *in vitro* antioxidant potential of the methanol extract of *Cyclotrichium niveum*. *Pharm Biol* 2009; 47(3): 219-229.
12. Gursoy N, Sihoglu-Tepe A, Tepe B. Determination of *in vitro* antioxidative and antimicrobial properties and total phenolic contents of *Ziziphora clinopodioides*, *Cyclotrichium niveum*, and *Mentha longifolia* ssp. *typhoides* var. *typhoides*. *J Med Food* 2009; 12(3):684-689.
13. Orhan I, Senol FS, Gülpinar AR, Kartal M, Sekeroglu N, Deveci M, et al. Acetylcholinesterase inhibitory and antioxidant properties of *Cyclotrichium niveum*, *Thymus praecox* subsp. *caucasicus* var. *caucasicus*, *Echinacea purpurea* and *E. pallida*. *Food Chem Toxicol* 2009; 47:1304-1310.
14. Reddy GR, Basha MR, Devi CB, Suresh A, Baker JL, Shafeek A, et al. Lead induced effects on acetylcholinesterase activity in cerebellum and hippocampus of developing rat. *Int J Dev Neurosci* 2003; 21(6):347–352.
15. Basha DC, Rani MU, Devi CB, Kumar MR, Reddy GR. Perinatal lead exposure alters postnatal cholinergic and aminergic system in rat brain: reversal effect of calcium co-administration. *Int J Dev Neurosci* 2012; 30:343-350.
16. Phyu MP, Tangpong J. Neuroprotective effects of xanthone derivative of *Garcinia mangostana* against lead-induced acetylcholinesterase dysfunction and cognitive impairment. *Food Chem Toxicol* 2014; 70:151-6.
17. Tangpong J, Satarug S. Alleviation of lead poisoning in the brain with aqueous leaf extract of the *Thunbergia laurifolia* (Linn.). *Toxicol Lett* 2010; 198:83-88.
18. Ellman GL, Andres DC. New and rapid colorimetric determination of acetylcholinesterase activity. *Biochem Pharmacol* 1961; 7:88–95.
19. Ozmen M, Dominguez SE, Fairbrother A. Effects of dietary azinphos methyl on selected plasma and tissue biomarkers of the gray-tailed vole. *Bull Environ Contam Toxicol* 1998; 60:194-201.
20. Bradford MM. A rapid sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem* 1976; 72:248–254.
21. Placer ZA, Cushman LL, Johnson BC. Estimation of product of lipid peroxidation (malonyl dialdehyde) in biochemical systems. *Analytical biochemistry* 1966; 16:359–364.
22. Moron MS, Depierre JW, Mannervik B. Levels of glutathione, glutathione reductase and glutathione S-transferase activities in rat lung and liver. *Biochim Biophys Acta* 1979; 582:67–78.
23. Carlberg I, Mannervik B. Purification and characterization of the flavoenzyme glutathione reductase from rat liver. *J Biol Chem* 1975; 250:5475–5480.
24. Habig WH, Pabst MJ, Jakoby WB. Glutathione S-transferases. The first enzymatic step in mercapturic acid formation. *J Biol Chem* 1974; 249(22):7130–7139.
25. Rattanachongkiat S, Millward GE, Foulkes ME. Determination

of arsenic species in fish, crustacean and sediment samples from Thailand using high performance liquid chromatography (HPLC) coupled with inductively coupled plasma mass spectrometry (ICP-MS). *J Environ Monit* 2004; 6(4):254-61.

26. De Blas Bravo I, Sanz Castro R, López Riquelme N, Tormo Díaz C, Apraiz Goyenaga D. Optimization of the trace element determination by ICP-MS in human blood serum. *J Trace Elem Med Biol* 2007; 21(Suppl 1):14-7.

27. Tüzmen MN, Yücel NC, Kalburcu T, Demiryas N. Effects of curcumin and tannic acid on the aluminum- and lead-induced oxidative neurotoxicity and alterations in NMDA receptors. *Toxicol Mech Methods*. 2015; 25(2):120-7.

28. Pedroso TF, Oliveira CS, Fonseca MM, Oliveira VA, Pereira ME. Effects of Zinc and N-Acetylcysteine in Damage Caused by Lead Exposure in Young Rats. *Biol Trace Elem Res* 2017; 180(2):275-284.

29. Inan M, Tel AZ. Determination of *Cyclotrichium niveum* Essential Oil and Its Components at Different Altitudes. *Not Bot Horti Agrobo* 2014; 42(1):128-131.

30. Shukla PK, Khanna VK, Khan MY, Srimal RC. Protective effect of curcumin against lead neurotoxicity in rat. *Hum Exp Toxicol* 2003; 22(12):653-8.

31. Saxena G, Pathak U, Flora SJS. Beneficial role of monoesters

of meso-2,3- dimercaptosuccinic acid in the mobilization of lead and recovery of tissue oxidative injury in rats. *Toxicology* 2005; 214:39–56.

32. Parke DV, Piotrowski J. Glutathione: Its role in detoxication of reactive oxygen and environmental chemicals. *Acta Pol Toxicol* 1996; 4:1-14.

33. Dringer A. Metabolism and function of glutathione in brain. *Prog Neurobiol* 2000; 62(6):649-71.

34. Reed DJ. Glutathione: Toxicological implications. *Annu Rev Pharmacol Toxicol* 1990; 30:603-31.

35. Strange C, Jones PW, Fryer AA. Glutathione S-transferase: genetics and role in toxicology. *Toxicol Lett* 2000; 112-113:357-63.

36. Boon PJ, Marinho HS, Oosting R, Mulder GJ. Glutathione conjugation of 4-hydroxy-trans-2.3-nonenal in the rat in vivo, the isolated perfused liver and erythrocytes. *Toxicol Appl Pharmacol*. 1999; 159(3):214-23.

37. Laurent A, Perdu-Durand E, Alary J, Debrauwer L, Cravedi JP. Metabolism of 4-hydroxynonenal, a cytotoxic product of lipid peroxidation, in rat precision-cut liver slices. *Toxicol Lett* 2000; 114(1-3):203-14.

38. Liu CM, Ma JQ, Sun YZ. Protective role of puerarin on lead-induced alterations of the hepatic glutathione antioxidant system and hyperlipidemia in rats. *Food Chem Toxicol* 2011; 49(12):3119-27.